Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02122211 · ClinicalTrials.gov registry record · Phase 1
Choline Dehydrogenase and Sperm Function: Effects of Betaine
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02122211 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 6 participants.
The verdict
NCT02122211, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The ability of sperm to swim is important for normal fertility. Men with a genetic variation in the gene coding for Choline Dehydrogenase (CHDH) have decreased energy production by sperm, and their sperm do not swim normally. The metabolic product of this gene is a nutrient called betaine (found normally in the diet as a part of many foods such as spinach, beets and grain products). This study tests whether treatment with betaine is safe and whether it can normalize energy production in sperm of these men and restore normal swimming ability.
Interventions
- DRUG Betaine supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02122211
The ClinicalTrials.gov registry entry for NCT02122211 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Betaine supplement is the first listed.
NCT02122211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02122211 about?
NCT02122211 is a clinical study titled "Choline Dehydrogenase and Sperm Function: Effects of Betaine". The ability of sperm to swim is important for normal fertility. Men with a genetic variation in the gene coding for Choline Dehydrogenase (CHDH) have decreased energy production by sperm, and their sperm do not swim normally. The metabolic product of this gene is a nutrient called betaine (found nor...
What is the current status of trial NCT02122211?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-04. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02122211?
The interventions under investigation include: Betaine supplement (DRUG).
Who is sponsoring clinical trial NCT02122211?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.